{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:41:34Z","timestamp":1776163294959,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Anti-CD20 monoclonal antibodies are a class of immunosuppressive drugs widely used in the treatment of central nervous system (CNS) inflammatory diseases, with well-established efficacy and safety. Although rare, these therapies can be associated with serious adverse events including hematological and infectious complications. This study aims to evaluate their safety and tolerability profile in real-world clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective cohort study comprising patients diagnosed with multiple sclerosis (MS) treated with anti-CD20 drugs since 2016 followed in the Demyelinating Diseases clinic of a tertiary center. Clinical and paraclinical parameters were evaluated, including complete blood count and immunoglobulins measurements.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 160 with multiple sclerosis (pwMS) were included in our study, of whom 110 (68.8%) were female and 147 are currently receiving anti-CD20 therapies. Half of the patients were diagnosed with relapsing\u2013remitting MS, while the remaining had progressive forms, including 23 with primary-progressive MS and 57 with secondary-progressive MS. Eighty-three patients were on ocrelizumab, 48 on rituximab, and 29 on ofatumumab. The mean follow-up duration from the start of anti-CD20 therapy was 30.5\u202f\u00b1\u202f21.3\u202fmonths. During this period, serious adverse events were observed in 9 patients, including SARS-CoV-2 infection (resulting in one death), urinary tract infection, febrile neutropenia, severe diarrhea, and acute hepatitis. The rate of serious infections in the ocrelizumab subgroup was consistent with the literature, although a higher rate was observed in the rituximab subgroup. A positive correlation was found between serious infectious complications and lower IgG levels. Additionally, longer exposure to anti-CD20 therapy in our cohort was associated with an increased risk of IgG deficiency and a higher incidence of serious infections. Lymphopenia was detected in 25 patients, though it was not directly linked to the occurrence of serious infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our work confirms the tolerability and safety of anti-CD20 drugs in a real-world clinical practice MS cohort, despite their frequent association with analytical changes such as lymphopenia and hypogammaglobulinemia. To better understand the clinical significance of hypogammaglobulinemia secondary to anti-CD20 treatment and to develop strategies for mitigating the associated potential infection risk, future studies with larger populations are essential.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1500763","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:15:21Z","timestamp":1736140521000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study"],"prefix":"10.3389","volume":"15","author":[{"given":"Andr\u00e9 Aires","family":"Fernandes","sequence":"first","affiliation":[]},{"given":"Ana L\u00eddia","family":"Neves","sequence":"additional","affiliation":[]},{"given":"Daniela","family":"Ferro","sequence":"additional","affiliation":[]},{"given":"Mafalda","family":"Seabra","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Mendon\u00e7a","sequence":"additional","affiliation":[]},{"given":"Ricardo Soares","family":"dos Reis","sequence":"additional","affiliation":[]},{"given":"Maria Jos\u00e9","family":"S\u00e1","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Guimar\u00e3es","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Abreu","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"102988","DOI":"10.1016\/j.msard.2021.102988","article-title":"Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases","volume":"52","author":"Oksbjerg","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.msard.2018.09.041","article-title":"Effectiveness and safety of rituximab in demyelinating diseases spectrum: an Italian experience","volume":"27","author":"D'Amico","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40259-018-0327-9","article-title":"Monoclonal antibodies for multiple sclerosis: an update","volume":"33","author":"Graf","year":"2019","journal-title":"BioDrugs"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jbspin.2009.03.010","article-title":"Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects","volume":"76","author":"Renaudineau","year":"2009","journal-title":"Joint Bone Spine"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2016","journal-title":"N Engl J Med"},{"key":"ref9","volume-title":"Ocrevus EPAR product information","year":"2018"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus Teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","article-title":"Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment","volume":"271","author":"Delgado","year":"2024","journal-title":"J Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"102466","DOI":"10.1016\/j.autrev.2020.102466","article-title":"Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia","volume":"19","author":"Kridin","year":"2020","journal-title":"Autoimmun Rev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"103418","DOI":"10.1016\/j.msard.2021.103418","article-title":"Derisking CD20-therapies for long-term use","volume":"57","author":"Smets","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/acn3.51282","article-title":"Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population","volume":"8","author":"Fernandez-Diaz","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"592304","DOI":"10.3389\/fneur.2020.592304","article-title":"Ocrelizumab in multiple sclerosis: a real-world study from Spain","volume":"11","author":"Sempere","year":"2020","journal-title":"Front Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e000108","DOI":"10.1136\/bmjno-2020-000108","article-title":"Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study","volume":"3","author":"Smoot","year":"2021","journal-title":"BMJ Neurol Open"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.msard.2018.05.011","article-title":"2017 McDonald diagnostic criteria: a review of the evidence","volume":"24","author":"McNicholas","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1212\/WNL.0000000000009636","article-title":"The 2013 clinical course descriptors for multiple sclerosis: a clarification","volume":"94","author":"Lublin","year":"2020","journal-title":"Neurology"},{"key":"ref21","volume-title":"Common terminology criteria for adverse events (CTCAE)","year":"2010"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1080\/21645515.2021.1969850","article-title":"Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis","volume":"17","author":"Gabeli\u0107","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40265-020-01437-2","article-title":"Alemtuzumab: a review in relapsing remitting multiple sclerosis","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"578066","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears","year":"2023","journal-title":"J Neuroimmunol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"104400","DOI":"10.1016\/j.msard.2022.104400","article-title":"Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease","volume":"68","author":"Peters","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s10067-016-3313-y","article-title":"Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature","volume":"35","author":"Monaco","year":"2016","journal-title":"Clin Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"109894","DOI":"10.1016\/j.clim.2024.109894","article-title":"Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab","volume":"259","author":"Beckers","year":"2024","journal-title":"Clin Immunol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1212\/WNL.0000000000006924","article-title":"Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis","volume":"92","author":"Cohen","year":"2019","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"116603","DOI":"10.1016\/j.jns.2019.116603","article-title":"Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature","volume":"409","author":"Zanetta","year":"2020","journal-title":"J Neurol Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"105009","DOI":"10.1016\/j.msard.2023.105009","article-title":"Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management","volume":"79","author":"Alvarez","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40263-021-00843-8","article-title":"Clinical perspectives on the molecular and pharmacological attributes of anti-CD20 therapies for multiple sclerosis","volume":"35","author":"Bar-Or","year":"2021","journal-title":"CNS Drugs"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"102787","DOI":"10.1016\/j.msard.2021.102787","article-title":"Comparison of the efficacy and safety of anti-CD20 B cells depleting drugs in multiple sclerosis","volume":"49","author":"Cotchett","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3390\/ijms18061249","article-title":"Emerging role of the spleen in the pharmacokinetics of monoclonal antibodies, nanoparticles and exosomes","volume":"18","author":"Cataldi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.neurol.2021.04.011","article-title":"Infections and multiple sclerosis: recommendations from the French Multiple Sclerosis Society","volume":"177","author":"Papeix","year":"2021","journal-title":"Rev Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"20552173211065731","DOI":"10.1177\/20552173211065731","article-title":"Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: a three-year observational cohort study","volume":"8","author":"Zingaropoli","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"102279","DOI":"10.1016\/j.msard.2020.102279","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis","volume":"44","author":"Baker","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1177\/1352458520952036","article-title":"De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis","volume":"27","author":"Disanto","year":"2021","journal-title":"Mult Scler"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1177\/1352458520949986","article-title":"Adverse event profile differences between rituximab and ocrelizumab: findings from the FDA adverse event reporting database","volume":"27","author":"Caldito","year":"2021","journal-title":"Mult Scler"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1500763\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:15:24Z","timestamp":1736140524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1500763\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":42,"alternative-id":["10.3389\/fneur.2024.1500763"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1500763","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"article-number":"1500763"}}